Baricitinib
Treatment for Covid 19
Typical Dosage: 4 mg orally once daily
Effectiveness
75%
Safety Score
55%
Clinical Trials
30
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
4 mg orally once daily
Time to Effect
7-14 days
Treatment Duration
14 days or until hospital discharge
Evidence Quality
HIGHNumber Needed to Treat (NNT)
25(Treat 25 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
150(Treat 150 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,200
Monitoring:$100
Side Effect Mgmt:$150
Total Annual:$1,450
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$33,000/QALY
QALYs Gained
0.02
Outcome-Based Costs
Cost per Responder
$2,230.77
Comparison vs Remdesivir + Dexamethasone
Cost Difference
+$1,000/year
More expensive
QALY Difference
+0.01 QALYs
Better outcomes
Dominance
No dominance
Baricitinib Outcomes
for Covid 19
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+65%
Common Side Effects
Infections
+8%
Thromboembolism
+3%
Elevated cholesterol/lipids
+7%
Anemia/neutropenia
+4%
Active Clinical Trials
1 active trial recruiting for Baricitinib in Covid 19
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
NCT06631287RECRUITINGPHASE3
550 participants
INTERVENTIONAL
San Francisco, United States +3 more
Started: Oct 21, 2024
Completed Clinical Trials
7 completed trials for Baricitinib in Covid 19
A Study of Baricitinib (LY3009104) in Participants With COVID-19
NCT04421027COMPLETEDPHASE3
1.52K participants
INTERVENTIONAL
Gilbert, United States +95 more
Started: Jun 12, 2020
Tocilizumab Versus Baricitinib in Patients With Severe COVID-19
NCT05082714COMPLETEDNA
251 participants
INTERVENTIONAL
Pátrai, Greece
Started: Oct 20, 2021
Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults
NCT04362943COMPLETED
576 participants
OBSERVATIONAL
Albacete, Spain
Started: Apr 20, 2020
Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
NCT04401579COMPLETEDPHASE3
1.03K participants
INTERVENTIONAL
Birmingham, United States +70 more
Started: May 8, 2020
Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
NCT04640168COMPLETEDPHASE3
1.01K participants
INTERVENTIONAL
Birmingham, United States +71 more
Started: Dec 2, 2020
Baricitinib Therapy in COVID-19
NCT04358614COMPLETEDPHASE2, PHASE3
12 participants
INTERVENTIONAL
Prato, Italy
Started: Mar 16, 2020
Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19
NCT04890626COMPLETEDPHASE3
356 participants
INTERVENTIONAL
Madrid, Spain
Started: Apr 4, 2020
Showing 20 of 30 total trials